` LUMO (Lumos Pharma Inc) vs S&P 500 Comparison - Alpha Spread

LUMO
vs
S&P 500

Over the past 12 months, LUMO has significantly outperformed S&P 500, delivering a return of 95% compared to the S&P 500's 10% growth.

Stocks Performance
LUMO vs S&P 500

Loading
LUMO
S&P 500
Add Stock

Performance Gap
LUMO vs S&P 500

Loading
LUMO
S&P 500
Difference
www.alphaspread.com

Performance By Year
LUMO vs S&P 500

Loading
LUMO
S&P 500
Add Stock

Competitors Performance
Lumos Pharma Inc vs Peers

S&P 500
LUMO
ABBV
AMGN
GILD
VRTX
Add Stock

Lumos Pharma Inc
Glance View

Market Cap
37.5m USD
Industry
Biotechnology

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. The company is headquartered in Austin, Texas and currently employs 29 full-time employees. The company went IPO on 2011-11-11. The firm is focused on identifying, acquiring, developing, and commercializing products and therapies for people with rare diseases. Its lead product candidate is LUM-201, a therapy for pediatric growth hormone deficiency (PGHD) and other rare endocrine disorders. LUM-201 stimulates growth hormone (GH) through the GH secretagogue receptor. Its product provides a differentiated mechanism of action to treat rare endocrine disorders by increasing the amplitude of endogenous and pulsatile GH secretion. LUM-201 is an orally administered small molecule, which is a GH secretagogue for rare endocrine disorders where injectable recombinant human growth hormone (rhGH) is approved. Its pipeline features development programs for rare diseases associated with growth hormone deficiencies. Its subsidiaries include NewLink International, BlueLink Pharmaceuticals, Inc, BioProtection Systems Corporation and Lumos Pharma Sub, Inc.

LUMO Intrinsic Value
17.2 USD
Undervaluation 75%
Intrinsic Value
Price
Back to Top